Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations

EFPIA Newsletter 9 June 2022


Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12)


The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the “Quad compromise” is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry’s ability to partner, invest at risk, and respond quickly to future pandemics. Read more




EFPIA statement on the concerning impact of the In Vitro Diagnostic Regulation
03 June 2022

Clinical trials in Europe might be reduced and access to novel therapies for patients delayed Read more




Europe’s Beating Cancer Plan is an investment, not a cost (Guest blog)
07 June 2022 - Gavin Lewis

With prevention and early diagnosis at the core, we call on the European Commission to continue to ensure that supporting... Read more

Be ambitious! Setting policy objectives for blood cancer (Guest blog)
08 June 2022 - Aoiffe O’Brien

It’s a great moment for the hematology community to stand up and advocate for explicit policy action on blood cancers... Read more


Back innovation, boost access

Innovation is only meaningful if patients get access to it. That’s why we are stepping up measures to help deliver faster, more equitable access to medicines for millions of patients across the EU.
Read more


Let's get medicines to patients faster
Patients in one part of Europe should not have to wait 7 times longer for a new medicine than those in another country.... Read more

Let's make access to medicines fairer
All European countries don’t have the same capacity to pay for healthcare. If we want to create a more equitable... Read more


Join us on 29 June


Job offer at IML


European Project Manager Country Engagement
On 08 June 2022 (IML)

IML, the organization representing the originator pharmaceutical industry in Luxembourg, is hiring an experienced... Read more